Liquiritigenin inhibits amyloid β-peptide-induced neurotozicity，the secretion of amyloid β-peptide a

• 作 者: Ruiting Liu Guangxing Bian Libo Zou Qiujun Lu
• 机 构: Institute of Radiation Medicine，Academy of Military Medical Science，Beijing，100850，China; School of
• 出 处: 2008年全国抗衰老与老年痴呆学术会议
• 发表日期: 2008年5期
• 关键词: liquiritegenin selectiveERβagonist neuroprotective Aβsecretion fibilformation

Background and Purpose: Amyloid β-peptide(AP) is a pivotal pathological factor in Alzheimers disease(AD). Estrogen is beneficial to patients with AD but its proliferation and oncogenic effects on non-neuronal cells has dampened the enthusiasm forthe use of estrogen in clinic. In an attempt to find estrogen substitutes that retain the beneficial effects of estrogen with minimal side effects，we have screened liquirigenin as a highly selective estrogen receptor β(Erβ) agonist. Considering estrogen has well established neuroprotection actions，in the present study，we examined the neuroprotective activities of liquiritigenin on Aβ(25-35)-induced damage and we analyzed actions of liquiritigenin on the secretion of Aβ(1-40) in a human neuroblastoma SH-SY5Y cell line. Then，we have externled our studies by testing whether liquiritigenin can inhibit fibrilformation. Finally，the related genes and protein were examined.